{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:50:52Z","timestamp":1793375452962,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.atherosclerosis.2024.118540","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T18:06:32Z","timestamp":1720721192000},"page":"118540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials"],"prefix":"10.1016","volume":"396","author":[{"given":"Pascal M.","family":"Burger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannick A.N.","family":"Dorresteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Koudstaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7616-3839","authenticated-orcid":false,"given":"Joris","family":"Holtrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wouter","family":"Jukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Mosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-5223","authenticated-orcid":false,"given":"Frank L.J.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.atherosclerosis.2024.118540_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118540_bib2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"34","key":"10.1016\/j.atherosclerosis.2024.118540_bib3","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.atherosclerosis.2024.118540_bib4","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of Cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2024.118540_bib5","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease","volume":"60","author":"Ference","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2024.118540_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease","volume":"322","author":"Ference","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118540_bib7","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118540_bib8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118540_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrcardio.2011.158","article-title":"Can we dramatically reduce the incidence of coronary heart disease?","volume":"8","author":"Domanski","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.118540_bib10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jacc.2009.12.057","article-title":"Earlier intervention in the management of hypercholesterolemia: what are we waiting for?","volume":"56","author":"Steinberg","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9435","key":"10.1016\/j.atherosclerosis.2024.118540_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118540_bib12","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study","volume":"44","author":"Koren","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2024.118540_bib13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2024.118540_bib14","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.118540_bib15","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118540_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-Dose atorvastatin after stroke or transient ischemic attack","volume":"355","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9346","key":"10.1016\/j.atherosclerosis.2024.118540_bib17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118540_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1541-0420.2010.01420.x","article-title":"Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring","volume":"67","author":"Geskus","year":"2011","journal-title":"Biometrics"},{"issue":"10170","key":"10.1016\/j.atherosclerosis.2024.118540_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Armitage","year":"2019","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2024.118540_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2024.118540_bib21","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2024.118540_bib22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.118540_bib23","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/eurheartj\/ehz239","article-title":"Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people","volume":"41","author":"Jaspers","year":"2020","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2024.118540_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009217","article-title":"Estimated life expectancy without recurrent cardiovascular events in patients with vascular disease: the SMART-REACH model","volume":"7","author":"Kaasenbrood","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2024.118540_bib25","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024011080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024011080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:48:57Z","timestamp":1727689737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024011080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":25,"alternative-id":["S0021915024011080"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118540","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"118540"}}